U.S. markets open in 5 hours 26 minutes
  • S&P Futures

    3,599.50
    -2.00 (-0.06%)
     
  • Dow Futures

    28,847.00
    +46.00 (+0.16%)
     
  • Nasdaq Futures

    10,989.00
    -46.50 (-0.42%)
     
  • Russell 2000 Futures

    1,673.80
    +4.00 (+0.24%)
     
  • Crude Oil

    82.90
    +3.41 (+4.29%)
     
  • Gold

    1,671.20
    -0.80 (-0.05%)
     
  • Silver

    19.34
    +0.31 (+1.61%)
     
  • EUR/USD

    0.9811
    +0.0010 (+0.10%)
     
  • 10-Yr Bond

    3.8040
    0.0000 (0.00%)
     
  • Vix

    32.65
    +0.81 (+2.54%)
     
  • GBP/USD

    1.1202
    +0.0036 (+0.32%)
     
  • USD/JPY

    145.0570
    +0.3280 (+0.23%)
     
  • BTC-USD

    19,203.32
    -81.52 (-0.42%)
     
  • CMC Crypto 200

    436.20
    -7.23 (-1.63%)
     
  • FTSE 100

    6,837.99
    -55.82 (-0.81%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

Longeveron to Release First Quarter 2021 Financial Results and Hold Conference Call on May 14, 2021

·2 min read

MIAMI, May 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first quarter 2021 financial results on Friday, May 14, 2021 before the open of US markets. Management will host a conference call on the same day at 8:30 AM.

To access the live conference, please dial 1-844-200-6205 from the United States or +44 208-0682-558 from other locations, and using entry code 460592. A webcast of the call may also be accessed from the ‘Investors’ page of the Longeveron website at www.longeveron.com. A replay of the call will be available on the Longeveron website shortly after completion of the call.

About Longeveron

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

Contact:
Brendan Payne
Stern Investor Relations
Tel: (212) 362-1200
Email: Brendan.payne@sternir.com

Source: Longeveron Inc
Source: LGVN